JAMES POOL to Hypertension
This is a "connection" page, showing publications JAMES POOL has written about Hypertension.
Connection Strength
2.762
-
Clinical role of direct renin inhibition in hypertension. Am J Ther. 2012 May; 19(3):204-10.
Score: 0.210
-
Effect of a physician uncertainty reduction intervention on blood pressure in uncontrolled hypertensives--a cluster randomized trial. J Gen Intern Med. 2012 Apr; 27(4):413-9.
Score: 0.202
-
The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial. Clin Drug Investig. 2009; 29(12):791-802.
Score: 0.166
-
Direct renin inhibition: focus on aliskiren. J Manag Care Pharm. 2007 Oct; 13(8 Suppl B):21-33.
Score: 0.153
-
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007 Jan; 20(1):11-20.
Score: 0.145
-
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007 Jan; 29(1):61-73.
Score: 0.145
-
Clinical pharmacology of antihypertensive therapy. Semin Nephrol. 2005 Jul; 25(4):215-26.
Score: 0.131
-
Is it time to move to multidrug combinations? Am J Hypertens. 2003 Nov; 16(11 Pt 2):36S-40S.
Score: 0.116
-
Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens. 2001 Jul; 15(7):495-8.
Score: 0.099
-
The role of angiotensin II in hypertension and end-organ damage. Int J Clin Pract Suppl. 2000 Aug; (111):4-8.
Score: 0.093
-
Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. Am J Hypertens. 1999 Sep; 12(9 Pt 1):906-14.
Score: 0.087
-
Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study. J Clin Pharmacol. 1999 May; 39(5):471-9.
Score: 0.085
-
Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999 Apr; 13(4):275-81.
Score: 0.085
-
A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group. Am J Hypertens. 1998 Apr; 11(4 Pt 1):454-61.
Score: 0.079
-
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998 Apr; 11(4 Pt 1):462-70.
Score: 0.079
-
Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens. 1997 Jan; 10(1):117-23.
Score: 0.072
-
Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Suppl. 1994 May; 74:13-7.
Score: 0.060
-
Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. Br J Clin Pract Suppl. 1994 May; 74:8-12.
Score: 0.060
-
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond). 2012 Feb; 122(4):193-202.
Score: 0.052
-
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J. 1991 Sep; 122(3 Pt 2):926-31.
Score: 0.050
-
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. J Clin Hypertens (Greenwich). 2011 May; 13(5):366-75.
Score: 0.048
-
Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J. 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60.
Score: 0.048
-
Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. Clin Ther. 1990 Nov-Dec; 12(6):520-33.
Score: 0.047
-
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations. J Hum Hypertens. 1990 Oct; 4 Suppl 3:23-33.
Score: 0.047
-
Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. Am J Med. 1989 Aug 16; 87(2A):57S-61S.
Score: 0.043
-
Does reducing physician uncertainty improve hypertension control?: rationale and methods. Circ Cardiovasc Qual Outcomes. 2009 May; 2(3):257-63.
Score: 0.043
-
Clinical experience and rationale for angiotensin-converting enzyme inhibition with lisinopril as the initial treatment for hypertension in older patients. Am J Med. 1988 Sep 23; 85(3B):19-24.
Score: 0.041
-
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Curr Med Res Opin. 2008 Apr; 24(4):1101-14.
Score: 0.039
-
Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension. Br J Clin Pract Suppl. 1987 Dec; 54:9-14.
Score: 0.039
-
Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1987; 9 Suppl 3:S36-42.
Score: 0.036
-
Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol. 2001 Mar 15; 87(6):727-31.
Score: 0.024
-
Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol. 1997 Oct; 80(4):521-32.
Score: 0.019
-
Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther. 1997 May-Jun; 19(3):447-58; discussion 367-8.
Score: 0.019
-
Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens. 1995 Feb; 8(2):133-45.
Score: 0.016
-
Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. J Clin Pharmacol. 1992 Apr; 32(4):351-9.
Score: 0.013
-
Nicardipine as antihypertensive monotherapy: positive effects on quality of life. J Hum Hypertens. 1991 Jun; 5(3):205-13.
Score: 0.012
-
Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. Am J Hypertens. 1988 Apr; 1(2):158-67.
Score: 0.010
-
Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. Am J Cardiol. 1987 May 29; 59(14):46G-50G.
Score: 0.009
-
Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist. Clin Pharmacol Ther. 1986 Dec; 40(6):694-7.
Score: 0.009
-
Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. J Cardiovasc Pharmacol. 1985 Jul-Aug; 7(4):767-76.
Score: 0.008
-
Propylbutyldopamine. Mechanism of blood pressure lowering in hypertensive patients. Hypertension. 1984 Mar-Apr; 6(2 Pt 2):I40-5.
Score: 0.007
-
Plasma concentrations of propranolol and 4-hydroxypropranolol in man measured by high pressure liquid chromatography. Life Sci. 1979 Jan 15; 24(3):209-17.
Score: 0.005
-
Plasma norepinephrine concentrations: no differences among normal volunteers and low, high or normal renin hypertensive patients. Life Sci. 1978 May 01; 22(17):1499-510.
Score: 0.005
-
Renin-aldosterone profiling in hypertension. Ann Intern Med. 1977 Nov; 87(5):596-312.
Score: 0.005